| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical compan...
 
																	
 
																	Maxim Group analyst Jason McCarthy upgrades Adial Pharmaceuticals (NASDAQ:ADIL) from Hold to Buy and announces $1.5 price ta...
 
																	Adial Pharmaceuticals received FDA backing for its Phase 3 AD04 trial, including endpoints and strategies for targeted populati...
 
																	Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical compan...
 
																	Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical compan...
 
																	Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of...
